The search bar is no longer the first stop for health questions. Today, patients type symptoms into ChatGPT before calling their pharmacist. Healthcare professionals ask Perplexity for mechanism-of-action summaries before opening a clinical database. According to Evertune's EverPanel research, 58% of people who visit biotech and pharma websites and use Google Search also use ChatGPT. The AI engine is now a primary point of pharmaceutical discovery, and the question is no longer whether this matters. The question is whether your product appears in those answers, and why.

At Aikka, we built the Pharma-GEO platform to answer exactly that. After analyzing AI citation patterns across hundreds of pharmaceutical queries, one structural insight stands out above all others: AI engines apply fundamentally different source hierarchies depending on whether a product is OTC or prescription. This is not a subtle variation. It is a bifurcation that should reshape how pharma companies think about their entire digital content strategy.

The Discovery: Two Products, Two AI Worlds

When a user asks ChatGPT about an antihistamine they can pick up at a pharmacy, the AI draws from a completely different pool of sources than when the same user asks about a reimbursed cardiovascular treatment. The regulatory status and reimbursement classification of a product effectively act as a filter that determines which content ecosystem the AI trusts.

This distinction has massive downstream consequences. If your GEO strategy treats an OTC brand the same as a prescription drug, you are almost certainly investing in the wrong content types, optimizing for the wrong platforms, and measuring the wrong signals.

OTC Products: Brand Sites Compete in a Noisy, Unverified Ecosystem

The most direct evidence of AI citation behavior for OTC products comes from a peer-reviewed study published in JMIR AI (Liu et al., 2025). Researchers analyzed Microsoft Copilot's citation behavior across 30 dietary supplements and 6 disease conditions, generating over 3,000 citations. The results are striking: 72.7% of all citations came from unverified or non-authoritative sources, including blogs, personal health articles, third-party sales sites, and social media. Unregulated medical knowledge websites, the catch-all category of personal blogs and lifestyle articles, alone accounted for 61.4% of citations.

Within the remaining verified citations, the hierarchy is revealing. Food and pharmaceutical manufacturer websites represented 7.8% of citations, narrowly ahead of academic and research sources at 7.3%. Government websites were nearly absent at just 1.5%. Put simply: for OTC and supplement queries, a brand's own website outranks PubMed, and both are dwarfed by bloggers.

This is the ecosystem in which OTC brands compete for AI visibility. The opportunity for brand.com content is real, but the threat is equally real. Uncontrolled, unverified content dominates, and your brand narrative can be displaced by a wellness blog that no human editor ever reviewed.

The INN displacement risk compounds this challenge. As Artefact's 2026 analysis notes: "Ask most AIs about allergy relief and you're more likely to get 'cetirizine 10mg' than a brand name, potentially bypassing years of advertising investment in a single response." When AI defaults to the generic name, the patient buys the cheapest available option. For OTC brands built on volume and premium positioning, that is precisely how market share erodes.

There is a positive data point here as well. Allegra's 2025 "Drowsy Prompts" campaign demonstrated that well-established OTC brand attributes, non-drowsiness in Allegra's case, are baked into AI training data through sheer corpus frequency. The campaign generated over half a billion impressions by leveraging something the brand discovered organically: AI already associates Allegra with alertness and Benadryl with sedation. For major OTC brands, this brand-attribute presence in AI outputs is an asset. For challenger brands or newer market entrants, it is a warning: without sustained content investment, you simply do not exist in the AI's mental model.

Platform choice also matters enormously for OTC strategy. Outcomes Rocket's cross-platform analysis (2025) found that Perplexity generates the most citations per response at 14.97 on average, and it favors commercial and user-generated content more than any other major AI engine. Gemini, by contrast, tends to favor brand-owned websites at 52% of citations. A well-structured OTC brand site with proper schema markup can genuinely compete for Gemini real estate in a way that has no equivalent for prescription drugs.

Prescription Products: Clinical Institutions Own the Conversation

Switch to a prescription drug query and the AI's sourcing logic changes completely. BrightEdge's 14-week analysis of over 113,000 URL-prompt pairs found that ChatGPT draws 27% of its healthcare citations from government sources (.gov domains), with an additional 17% from medical specialty organizations. Elite hospital systems, clinical guidelines, and institutional health authorities make up the remainder. The brand manufacturer's website is, in most cases, invisible.

Stanford's SourceCheckup study, published in Nature Communications, confirmed that when LLMs do cite sources for health queries, those sources are concentrated at mayoclinic.com, nih.gov, and cdc.gov, not pharmaceutical brand domains. Separately, a January 2026 arXiv analysis (Jacques et al.) found that over 75% of ChatGPT's health citations came from established institutional sources: Mayo Clinic, Cleveland Clinic, the National Health Service, and PubMed-indexed content.

The GLP-1 drug category illustrates this dynamic at scale. When someone asks ChatGPT about Wegovy or Mounjaro, the responses are shaped by the SELECT and SURMOUNT trial publications, FDA approval announcements, NEJM articles, and government health resources. The drug manufacturer's own website rarely appears as a primary citation. According to Metricus AI's 2025 testing, Pfizer is mentioned in 85% or more of AI responses to treatment queries, and Johnson & Johnson in roughly 80%, not because their brand sites are well-optimized, but because their clinical publication volume is so vast that the AI has encountered their drugs thousands of times in authoritative contexts. Mid-size biotechs, by contrast, appear in fewer than 5% of responses.

For specialist clinical AI tools used by physicians at point of care, the situation is even more stark. Platforms like Open Evidence and ClinicalKey AI use retrieval-augmented generation (RAG) to pull exclusively from curated medical databases: PubMed, Cochrane reviews, and published clinical guidelines. Brand.com content is, as Artefact's framework describes it, "essentially invisible" in this environment unless it exists in structured clinical form.

Why This Split Exists

The divergence is not arbitrary. Three structural forces drive it.

First, regulatory intent signals. Prescription drug queries trigger what AI researchers call YMYL (Your Money or Your Life) classification. AI systems apply stricter authority thresholds to responses that could influence medical decisions, pushing the output toward institutional and clinical content.

Second, content ecology. The web ecosystem around OTC products is built on consumer intent: lifestyle content, product comparisons, affiliate reviews, wellness blogs. The web ecosystem around prescription drugs is built on clinical intent: trial registrations, PubMed abstracts, FDA labeling databases, and guideline documents. AI training reflects the content that exists.

Third, brand name versus INN dynamics. Clinical literature uses international nonproprietary names. When a drug's primary content footprint is in clinical literature, the AI learns to refer to it by its INN, not its brand. For prescription drugs, this means the marketing investment in a brand name competes against the sheer volume of INN references in peer-reviewed sources.

What Pharma Can Do: Strategy Must Match Product Type

The most important takeaway from Pharma-GEO platform analysis is that a single GEO strategy cannot serve both product types. The levers are different, the content targets are different, and the platforms that matter are different.

For OTC brands, the priorities are: ensuring INN-to-brand pairing is explicit across all indexed content; investing in structured brand.com architecture with FAQPage and MedicalCondition schema markup to compete in Gemini and Google AI Overviews; monitoring unregulated content that may be displacing brand narratives on Copilot and Bing; and building content presence in the third-party health media that platforms like Perplexity favor. As Princeton's foundational GEO research demonstrated, citing authoritative sources within your own content increases generative engine visibility by up to 29%, and including expert quotations increases it by up to 41%. These are techniques OTC brands can apply to their consumer-facing content immediately.

For prescription drug brands, the priorities are different in kind: clinical publication indexing is the primary lever, not brand.com content. Structured PubMed abstracts, INN-brand pairing in published trial metadata, FDA label completeness on DailyMed, and presence in medical guidelines are the content types that determine AI visibility with both generalist engines and specialist clinical AI. As CMI Media Group's analysis shows, 75% of non-branded pharma keyword queries now trigger AI Overviews, where clinical content structurally dominates. The window for brand content is narrow, concentrated around the 34% of branded keyword queries where Overviews appear. Investing in medical affairs content formatted as clinical FAQs, patient education pages with structured data, and syndicated summaries on medical news outlets gives prescription brands their best path to AI surface presence.

For all pharma companies, the urgency is real. Click-through rates on pharma search results dropped from 32% to 27% in a single year as AI summaries absorb query intent, according to CMI Media Group. As Artefact's research notes, reformatting existing pharmaceutical content assets for AI consumption can improve citation rates by up to 40%. The investment required is not always large. The cost of inaction, however, is measurable and growing.

Conclusion

AI engines are not neutral conduits for pharmaceutical information. They are systems with distinct trust architectures, and those architectures respond differently depending on whether your product sits on a pharmacy shelf or behind a prescription. The Pharma-GEO platform exists to make this difference visible and actionable, mapping exactly where your products appear, which sources the AI trusts for your category, and what content investments would change that picture.

If you want to see how your portfolio performs in this new landscape, request a sample Pharma-GEO report at app.pharma-geo.com. The data will not look the same for your OTC brands and your reimbursed products. That asymmetry is precisely the point.

See how your brand appears in AI answers.

Get a cross-LLM reputation report in minutes. No patient data. EU-based storage.

Book a demo Request a sample report

Data source: PharmaGEO platform analysis and cross-platform AI citation research (2025-2026)